Ken Fisher Fisher Asset Management
Ken Fisher is the founder and executive chairman of Fisher Investments, a global money management firm overseeing billions of dollars in assets. He gained early recognition for pioneering the use of the price-to-sales ratio in stock analysis and wrote the long-running “Portfolio Strategy” column in Forbes. Over the years, Fisher has authored numerous books on investing and wealth management, many of which have become bestsellers.
Top Buys
| Rank | Stock | Value |
|---|---|---|
| 1 |
Johnson & Johnson
JNJ
|
+$907M |
| 2 |
Apple
AAPL
|
+$260M |
| 3 |
Microsoft
MSFT
|
+$223M |
| 4 |
Amazon
AMZN
|
+$173M |
| 5 |
Alphabet (Google) Class A
GOOGL
|
+$160M |
Top Sells
| Rank | Stock | Value |
|---|---|---|
| 1 |
Eli Lilly
LLY
|
+$471M |
| 2 |
NVO
Novo Nordisk
NVO
|
+$177M |
| 3 |
AZPN
ASPEN TECHNOLOGY INC
AZPN
|
+$160M |
| 4 |
Petrobras
PBR
|
+$153M |
| 5 |
Adobe
ADBE
|
+$146M |
Sector Composition
| Rank | Sector | Weight |
|---|---|---|
| 1 | Technology | 27.79% |
| 2 | Healthcare | 12.41% |
| 3 | Financials | 9.98% |
| 4 | Consumer Discretionary | 9.11% |
| 5 | Communication Services | 6.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Change in Stake | Capital Flow | |
|---|---|---|---|---|---|---|
26
iShares 7-10 Year Treasury Bond ETF
IEF
$47B
| $1.27B | 0.9% |
12,459,743
+110,380
| +0.9% | +$11.3M |
|
27
Thermo Fisher Scientific
TMO
$210B
| $1.27B | 0.9% |
2,340,814
+83,936
| +4% | +$46.2M |
|
28
NextEra Energy
NEE
$182B
| $1.26B | 0.89% |
16,228,364
+564,306
| +4% | +$43M |
|
29
PayPal
PYPL
$49B
| $1.21B | 0.86% |
17,329,942
+552,397
| +3% | +$47.9M |
|
30
Oracle
ORCL
$375B
| $1.21B | 0.86% |
17,301,215
+542,384
| +3% | +$39.7M |
|
31
NVIDIA
NVDA
$4.81T
| $1.15B | 0.81% |
75,911,860
+2,628,140
| +4% | +$49.6M |
|
32
Netflix
NFLX
$301B
| $1.15B | 0.81% |
65,483,030
+1,922,090
| +3% | +$42.6M |
|
33
Union Pacific
UNP
$172B
| $1.12B | 0.79% |
5,258,523
+149,603
| +3% | +$34M |
|
34
Merck
MRK
$319B
| $1.11B | 0.78% |
12,123,820
+291,723
| +2% | +$25.9M |
|
35
Shell
SHEL
$253B
| $1.06B | 0.75% |
20,255,325
+659,109
| +3% | +$37M |
|
36
Abbott
ABT
$179B
| $1.02B | 0.72% |
9,390,366
+276,309
| +3% | +$31.4M |
|
|
37
Johnson & Johnson
JNJ
$612B
| $1.02B | 0.72% |
5,729,930
+5,091,698
| +798% | +$907M |
|
38
BHP
BHP
$215B
| $1.01B | 0.72% |
18,027,616
-922,776
| -5% | -$57.3M |
|
39
Goldman Sachs
GS
$304B
| $976M | 0.69% |
3,286,827
+113,329
| +4% | +$35.3M |
|
40
Chevron
CVX
$384B
| $976M | 0.69% |
6,739,795
+158,766
| +2% | +$26.2M |
|
41
Danaher
DHR
$137B
| $973M | 0.69% |
4,330,431
+105,929
| +3% | +$24.4M |
|
42
Novartis
NVS
$296B
| $951M | 0.67% |
11,246,080
+375,047
| +3% | +$32.9M |
|
43
Intuitive Surgical
ISRG
$126B
| $923M | 0.65% |
4,600,358
+108,521
| +2% | +$25.5M |
|
44
Intuit
INTU
$85.8B
| $907M | 0.64% |
2,352,591
+186,794
| +9% | +$77.3M |
|
45
Rio Tinto
RIO
$156B
| $906M | 0.64% |
14,846,876
+717,951
| +5% | +$51.5M |
|
46
JPMorgan Chase
JPM
$930B
| $900M | 0.64% |
7,989,439
+229,353
| +3% | +$28.4M |
|
47
Sanofi
SNY
$102B
| $881M | 0.62% |
17,612,672
-320,069
| -2% | -$17M |
|
48
Verizon
VZ
$190B
| $880M | 0.62% |
17,336,618
+549,117
| +3% | +$27.8M |
|
49
Nike
NKE
$62.1B
| $873M | 0.62% |
8,541,187
+256,322
| +3% | +$30.3M |
|
50
GSK
GSK
$103B
| $852M | 0.6% |
15,654,499
+480,732
| +3% | +$26.5M |
|
Similar funds
Ken Fisher's Q2 2022 Portfolio in Review
As of Q2 2022, Ken Fisher held 1,196 positions worth $141B, down 17% from $169B the previous quarter. Its ten largest holdings account for 30% of the portfolio.
Ken Fisher's Q2 2022 filing shows 110 new, 483 increased, 318 reduced and 131 closed positions. Its largest new stake was Woodside Energy: 6,156,348 shares worth $133M. The largest sale was Eli Lilly, an estimated $471M.
By sector, the portfolio is most concentrated in Technology at 28% of assets, down from 29% a quarter earlier, followed by Healthcare and Financials.
- Ken Fisher's largest Q2 2022 buy was Woodside Energy: 6,156,348 shares worth $133M.
- Ken Fisher added most to Johnson & Johnson in Q2 2022, an estimated $907M increase.
- Ken Fisher's biggest Q2 2022 reduction was Eli Lilly, cutting an estimated $471M.
- Ken Fisher fully exited ASPEN TECHNOLOGY INC in Q2 2022, selling an estimated $160M.
- Ken Fisher's ten largest holdings make up 30% of its $141B portfolio in Q2 2022.
- Ken Fisher opened 110 new positions and closed 131 in Q2 2022.
- Ken Fisher's portfolio value fell 17% quarter-over-quarter to $141B.
Based on Fisher Asset Management's 13F filing for Q2 2022, filed 9 Aug 2022.